Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash Items
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Cash from Operations: 2023-2025

Historic Cash from Operations for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to -$177,000.

  • BioLineRx's Cash from Operations rose 98.44% to -$177,000 in Q2 2025 from the same period last year, while for Jun 2025 it was -$21.2 million, marking a year-over-year increase of 30.13%. This contributed to the annual value of -$43.9 million for FY2024, which is 94.06% down from last year.
  • BioLineRx's Cash from Operations amounted to -$177,000 in Q2 2025, which was up 93.17% from -$2.6 million recorded in Q1 2025.
  • BioLineRx's 5-year Cash from Operations high stood at $5.0 million for Q4 2023, and its period low was -$14.1 million during Q1 2024.
  • Over the past 3 years, BioLineRx's median Cash from Operations value was -$9.1 million (recorded in 2023), while the average stood at -$6.9 million.
  • Per our database at Business Quant, BioLineRx's Cash from Operations plummeted by 272.51% in 2024 and then skyrocketed by 98.44% in 2025.
  • Over the past 3 years, BioLineRx's Cash from Operations (Quarterly) stood at $5.0 million in 2023, then slumped by 272.51% to -$8.6 million in 2024, then spiked by 98.44% to -$177,000 in 2025.
  • Its Cash from Operations was -$177,000 in Q2 2025, compared to -$2.6 million in Q1 2025 and -$8.6 million in Q4 2024.